ABBV Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of 10.92% compared to AbbVie, Inc.'s net margin of -2.24%. AbbVie, Inc.'s return on equity of 144.3% beat Biogen, Inc.'s return on equity of 7.36%.

AbbVie, Inc. has a consensus price target of $247.30, signalling upside risk potential of 10.23%. On the other hand Biogen, Inc. has an analysts' consensus of $205.52 which suggests that it could grow by 7%. Given that AbbVie, Inc. has higher upside potential than Biogen, Inc., analysts believe AbbVie, Inc. is more attractive than Biogen, Inc..

AbbVie, Inc. has a beta of 0.350, which suggesting that the stock is 64.985% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.160, suggesting its less volatile than the S&P 500 by 84.033%.

AbbVie, Inc. has a quarterly dividend of $1.73 per share corresponding to a yield of 2.96%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AbbVie, Inc. pays 279% of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

AbbVie, Inc. quarterly revenues are $16.6B, which are larger than Biogen, Inc. quarterly revenues of $2.2B. AbbVie, Inc.'s net income of $1.8B is higher than Biogen, Inc.'s net income of -$48.9M. Notably, AbbVie, Inc.'s price-to-earnings ratio is 94.78x while Biogen, Inc.'s PE ratio is 21.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.50x versus 2.96x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of 10.92% compared to AbbVie, Inc.'s net margin of 27.55%. AbbVie, Inc.'s return on equity of 144.3% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

AbbVie, Inc. has a consensus price target of $247.30, signalling upside risk potential of 10.23%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $155.42 which suggests that it could grow by 2.85%. Given that AbbVie, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe AbbVie, Inc. is more attractive than Gilead Sciences, Inc..

AbbVie, Inc. has a beta of 0.350, which suggesting that the stock is 64.985% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.

AbbVie, Inc. has a quarterly dividend of $1.73 per share corresponding to a yield of 2.96%. Gilead Sciences, Inc. offers a yield of 2.09% to investors and pays a quarterly dividend of $0.79 per share. AbbVie, Inc. pays 279% of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.61% of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie, Inc.'s is not.

AbbVie, Inc. quarterly revenues are $16.6B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.9B. AbbVie, Inc.'s net income of $1.8B is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, AbbVie, Inc.'s price-to-earnings ratio is 94.78x while Gilead Sciences, Inc.'s PE ratio is 22.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.50x versus 6.45x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 10.92% compared to AbbVie, Inc.'s net margin of 20.83%. AbbVie, Inc.'s return on equity of 144.3% beat Johnson & Johnson's return on equity of 34.46%.

AbbVie, Inc. has a consensus price target of $247.30, signalling upside risk potential of 10.23%. On the other hand Johnson & Johnson has an analysts' consensus of $232.50 which suggests that it could fall by -5.84%. Given that AbbVie, Inc. has higher upside potential than Johnson & Johnson, analysts believe AbbVie, Inc. is more attractive than Johnson & Johnson.

AbbVie, Inc. has a beta of 0.350, which suggesting that the stock is 64.985% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

AbbVie, Inc. has a quarterly dividend of $1.73 per share corresponding to a yield of 2.96%. Johnson & Johnson offers a yield of 2.08% to investors and pays a quarterly dividend of $1.30 per share. AbbVie, Inc. pays 279% of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie, Inc.'s is not.

AbbVie, Inc. quarterly revenues are $16.6B, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. AbbVie, Inc.'s net income of $1.8B is lower than Johnson & Johnson's net income of $5.1B. Notably, AbbVie, Inc.'s price-to-earnings ratio is 94.78x while Johnson & Johnson's PE ratio is 22.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.50x versus 6.36x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 10.92% compared to AbbVie, Inc.'s net margin of 34.4%. AbbVie, Inc.'s return on equity of 144.3% beat Eli Lilly & Co.'s return on equity of 104.39%.

AbbVie, Inc. has a consensus price target of $247.30, signalling upside risk potential of 10.23%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,206.07 which suggests that it could grow by 17.87%. Given that Eli Lilly & Co. has higher upside potential than AbbVie, Inc., analysts believe Eli Lilly & Co. is more attractive than AbbVie, Inc..

AbbVie, Inc. has a beta of 0.350, which suggesting that the stock is 64.985% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

AbbVie, Inc. has a quarterly dividend of $1.73 per share corresponding to a yield of 2.96%. Eli Lilly & Co. offers a yield of 0.61% to investors and pays a quarterly dividend of $1.73 per share. AbbVie, Inc. pays 279% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie, Inc.'s is not.

AbbVie, Inc. quarterly revenues are $16.6B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. AbbVie, Inc.'s net income of $1.8B is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, AbbVie, Inc.'s price-to-earnings ratio is 94.78x while Eli Lilly & Co.'s PE ratio is 45.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.50x versus 14.30x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.